Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer
2006

Corticosteroid Co-Treatment and Chemotherapy Resistance in Pancreatic Cancer

Sample size: 30 publication 15 minutes Evidence: high

Author Information

Author(s): Zhang Chengwen, Kolb Armin, Büchler Peter, Cato Andrew CB, Mattern Jürgen, Rittgen Werner, Edler Lutz, Debatin Klaus-Michael, Büchler Markus W, Friess Helmut, Herr Ingrid

Primary Institution: German Cancer Research Center

Hypothesis

Does dexamethasone induce resistance to chemotherapy in pancreatic cancer cells?

Conclusion

Dexamethasone induces therapy resistance in pancreatic carcinoma cells, raising concerns about its use in cancer treatment.

Supporting Evidence

  • Dexamethasone inhibited drug-induced apoptosis in all examined malignant cells.
  • In 18 of 20 cell lines from resected tumors, dexamethasone significantly prevented the cytotoxic effects of chemotherapy.
  • In vivo, dexamethasone completely prevented the cytotoxicity of chemotherapy in xenografted pancreatic carcinoma cells.

Takeaway

Giving a medicine called dexamethasone with cancer treatment can make the cancer cells stronger and harder to kill.

Methodology

The study used pancreatic cancer cell lines, surgical resections, and xenografts in mice to assess the effects of dexamethasone on chemotherapy resistance.

Potential Biases

Potential bias due to the lack of randomized controlled trials evaluating the impact of glucocorticoids on solid tumors.

Limitations

The study did not correlate therapy resistance with patient demographics such as age, gender, or tumor stage.

Participant Demographics

Patients with pancreatic cancer, demographics not specified.

Statistical Information

P-Value

0.0063

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-6-61

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication